news

InVivo Therapeutics announces uplisting to Nasdaq

Posted: 16 April 2015 |

InVivo Therapeutics Holdings Corp. (NVIV) has announced that its common stock has been approved to begin trading on The Nasdaq Capital Market…

cordis

InVivo Therapeutics Holdings Corp. (NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, has announced that its common stock has been approved to begin trading on The Nasdaq Capital Market.

invivo therapeutics

The Company’s common stock will begin trading under the symbol “NVIV” at the opening of trading on Friday, April 17, 2015.

InVivo Therapeutics now better positioned to attract institutional investors

“We are pleased to reach this important corporate milestone. InVivo has made significant progress spanning all areas of the organization over the last year and uplisting to Nasdaq will allow us to communicate this progress with a broader audience. We are now better positioned to enhance stock liquidity and attract institutional investors, which will fundamentally enhance the value of our company,” said Mark Perrin, InVivo’s Chief Executive Officer and Chairman of the Board.

The Company’s management have been invited to ring The Nasdaq Stock Market Opening Bell on Friday 17 April 2015.

Additional discussion of the benefits of a NASDAQ listing can be found at “CEO’s Perspective” on the InVivo Therapeutics website.

For more information about InVivo Therapeutics, please visit www.invivotherapeutics.com.

Related organisations